Immunicum AB reveals positive Phase II MERECA clinical trial data
Category: #health  By Paroma Bhattacharya  Date: 2019-08-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Immunicum AB reveals positive Phase II MERECA clinical trial data

Satisfactory safety profile and the positive number of complete responses by the trials firmly justify the prolonged clinical advancement of ilixadencel as an immune primer in solid tumors.

Immunicum AB (publ), a Swedish biopharmaceutical company, has recently announced positive results from the Phase II MERECA (Metastatic Renal Cell Carcinoma) clinical trials which was focused on evaluating the therapeutic impact of merging Sutent® (sunitinib) with ilixadencel.

As per reports, the most significant outcome of this trial was getting 5 complete responses, defined as no further evidence of disease and eradication of the cancerous tumor, without the additional toxicity created by ilixadencel.

However, the median overall survival has not been achieved yet due to a high rate of overall survival in both study arms. The result also validates the continued clinical development of ilixadencel in other solid tumor indications as well as in kidney cancer.

Speaking on the announcement, Dr. Magnus Lindskog, MERECA investigator and Associate Professor at Uppsala University Hospital, said that being a clinical oncologist who specializes in treating kidney cancer patients, the potential of an immune primer that can uphold the advancement of complete responses in advanced-stage patients with a progressive safety profile and tolerability is very exciting, particularly in an indication where a complete response is rare.

He said that it would be a major step forward for the treatment of kidney cancer if this response rate can be replicated on a bigger pivotal trial.

As for Carlos de Sousa, CEO, Immunicum AB (publ), the company’s main aim from MERECA trials was to study the therapeutic benefit of ilixadencel when merged with a standard treatment regimen. Moreover, the astounding number of complete responses in advanced-stage cancer patients is reassuring and highly supportive of their idea for ilixadencel as primary therapy in modern cancer treatment options.

He further added that the company is eager to conduct the complete investigation of the data and use it to accelerate and refine ilixadencel’s clinical advancements.

Source Credit: https://immunicum.se/investors/press-releases/press/?xml_id=1908171

 



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program
Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program
By Paroma Bhattacharya

Type 2 diabetes is a prevailing disease in which cells become unresponsive to insulin while gradually increasing blood sugar. With growing cases of Type 2 diabetes worldwide, pharmaceutical companies are now focusing o...

Poxel commences its Phase 1b trial for NASH drug candidate, PXL065
Poxel commences its Phase 1b trial for NASH drug candidate, PXL065
By Paroma Bhattacharya

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by the buildup of fat in the liver mostly with people who drink little or no alcohol. With growing cases of NASH prevailing worldwide, pharmaceutical com...

Flipkart extents delivery reach by 80% to cover more pincodes in India
Flipkart extents delivery reach by 80% to cover more pincodes in India
By Paroma Bhattacharya

  • The e-commerce site has managed to grow its reach to an estimate of 19,200 PIN codes from its prior 10,660 last year for the delivery of huge appliances.